BR112023001362A2 - Métodos para redução da concentração de glicoesfingolipídio no tecido cerebral e métodos de tratamento doenças neurodegenerativas envolvendo os mesmos - Google Patents
Métodos para redução da concentração de glicoesfingolipídio no tecido cerebral e métodos de tratamento doenças neurodegenerativas envolvendo os mesmosInfo
- Publication number
- BR112023001362A2 BR112023001362A2 BR112023001362A BR112023001362A BR112023001362A2 BR 112023001362 A2 BR112023001362 A2 BR 112023001362A2 BR 112023001362 A BR112023001362 A BR 112023001362A BR 112023001362 A BR112023001362 A BR 112023001362A BR 112023001362 A2 BR112023001362 A2 BR 112023001362A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- brain tissue
- neurodegenerative diseases
- diseases involving
- concentration
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 8
- 210000005013 brain tissue Anatomy 0.000 title abstract 4
- 150000002339 glycosphingolipids Chemical class 0.000 title abstract 3
- 238000011282 treatment Methods 0.000 title abstract 3
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract 2
- 102100033342 Lysosomal acid glucosylceramidase Human genes 0.000 abstract 3
- 230000035772 mutation Effects 0.000 abstract 2
- 206010067889 Dementia with Lewy bodies Diseases 0.000 abstract 1
- 108010017544 Glucosylceramidase Proteins 0.000 abstract 1
- 201000002832 Lewy body dementia Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 230000008482 dysregulation Effects 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 150000008584 quinuclidines Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063059047P | 2020-07-30 | 2020-07-30 | |
| US202063131120P | 2020-12-28 | 2020-12-28 | |
| PCT/IB2021/056971 WO2022024062A1 (en) | 2020-07-30 | 2021-07-30 | Methods for reducing glycosphingolipid concentration in brain tissue and methods of treatment of neurodegenerative diseases involving the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023001362A2 true BR112023001362A2 (pt) | 2023-02-14 |
Family
ID=77265125
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023001362A BR112023001362A2 (pt) | 2020-07-30 | 2021-07-30 | Métodos para redução da concentração de glicoesfingolipídio no tecido cerebral e métodos de tratamento doenças neurodegenerativas envolvendo os mesmos |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230372313A1 (https=) |
| EP (1) | EP4188381A1 (https=) |
| JP (1) | JP2023535483A (https=) |
| KR (1) | KR20230047146A (https=) |
| CN (1) | CN116322679A (https=) |
| AU (1) | AU2021317180A1 (https=) |
| BR (1) | BR112023001362A2 (https=) |
| CA (1) | CA3187086A1 (https=) |
| IL (1) | IL300096A (https=) |
| MX (1) | MX2023001285A (https=) |
| WO (1) | WO2022024062A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114040762A (zh) | 2019-02-04 | 2022-02-11 | 建新公司 | 使用葡糖神经酰胺合酶(gcs)的抑制剂治疗纤毛疾病 |
| KR20260021150A (ko) | 2024-08-05 | 2026-02-13 | 충북대학교 산학협력단 | Gba1 돌연변이 보인자의 dj-1 발현수준에 따른 파킨슨병의 위험도 예측 방법 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| KR101987736B1 (ko) * | 2011-03-18 | 2019-06-11 | 젠자임 코포레이션 | 글루코실세라마이드 합성효소 억제제 |
| JO3713B1 (ar) | 2013-03-15 | 2021-01-31 | Genzyme Corp | أشكال ملح (s)-كوينوكليدين-3-يل(2-(2-(4-فلوروفينيل)ثيازول-4-يل)بروبان-2-يل)كارباميت |
| TW201642855A (zh) | 2015-03-10 | 2016-12-16 | 健臻公司 | 用於治療蛋白質病變之方法 |
| US10617713B2 (en) * | 2016-03-08 | 2020-04-14 | Neurocentria, Inc. | Methods of modifying neuronal function by changing intracellular magnesium levels |
| EP3452045A1 (en) * | 2016-05-04 | 2019-03-13 | Lysosomal Therapeutics Inc. | Methods of treatment and combination therapies using gcase activator heterobicyclic and related compounds |
| US10519157B2 (en) * | 2018-02-09 | 2019-12-31 | X-Cutag Therapeutics, Inc. | Deuterated compounds for treating Fabry, Gaucher, Parkinson's and related diseases and conditions, and compositions and methods thereof |
-
2021
- 2021-07-30 US US18/007,433 patent/US20230372313A1/en active Pending
- 2021-07-30 CA CA3187086A patent/CA3187086A1/en active Pending
- 2021-07-30 EP EP21752208.5A patent/EP4188381A1/en active Pending
- 2021-07-30 WO PCT/IB2021/056971 patent/WO2022024062A1/en not_active Ceased
- 2021-07-30 BR BR112023001362A patent/BR112023001362A2/pt unknown
- 2021-07-30 CN CN202180065014.XA patent/CN116322679A/zh active Pending
- 2021-07-30 AU AU2021317180A patent/AU2021317180A1/en active Pending
- 2021-07-30 MX MX2023001285A patent/MX2023001285A/es unknown
- 2021-07-30 JP JP2023505841A patent/JP2023535483A/ja active Pending
- 2021-07-30 KR KR1020237007140A patent/KR20230047146A/ko active Pending
- 2021-07-30 IL IL300096A patent/IL300096A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022024062A1 (en) | 2022-02-03 |
| CN116322679A (zh) | 2023-06-23 |
| EP4188381A1 (en) | 2023-06-07 |
| JP2023535483A (ja) | 2023-08-17 |
| MX2023001285A (es) | 2023-02-22 |
| IL300096A (en) | 2023-03-01 |
| AU2021317180A1 (en) | 2023-03-23 |
| US20230372313A1 (en) | 2023-11-23 |
| KR20230047146A (ko) | 2023-04-06 |
| CA3187086A1 (en) | 2022-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gehring et al. | A randomized trial on the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary brain tumor | |
| BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
| BR112022000019A2 (pt) | Composto da fórmula, composição farmacêutica e método de tratamento de câncer | |
| BR112018000041A2 (pt) | Derivados de carbamato de 1,1,1-trifluoro-3- hidroxipropan-2-ila e derivados de carbamato de 1,1,1-trifluoro-4-hidroxibutan-2-ila como inibidores de magl | |
| Zaccara et al. | Placebo and nocebo responses in drug trials of epilepsy | |
| BRPI0712322A2 (pt) | compostos e combinações destes para a inibição da produção de beta-amilóide e métodos de uso dos mesmos | |
| EA018006B1 (ru) | α-АМИНОАМИДНЫЕ ПРОИЗВОДНЫЕ, ПОЛЕЗНЫЕ В ЛЕЧЕНИИ КОГНИТИВНЫХ РАССТРОЙСТВ | |
| BR112014004845A2 (pt) | pelo menos uma entidade química; pelo menos um composto; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada | |
| BR112012015499A2 (pt) | método de tratamento de fibrilação atrial | |
| BRPI0608205A2 (pt) | derivado heterocìclico-1-carboxilato de piridila não-aromático nitrogenado | |
| BR112014004741A2 (pt) | pelo menos uma entidade química; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada | |
| BR112023001362A2 (pt) | Métodos para redução da concentração de glicoesfingolipídio no tecido cerebral e métodos de tratamento doenças neurodegenerativas envolvendo os mesmos | |
| Weiss et al. | Combined stimulation of the substantia nigra pars reticulata and the subthalamic nucleus is effective in hypokinetic gait disturbance in Parkinson’s disease | |
| BR112022021823A2 (pt) | Métodos para tratar doenças associadas à mielina e doenças associadas à mitocôndria | |
| MX2024014117A (es) | Sales de ácido piperidinil-metil-purina-amina-d-tartárico, formas cristalinas y su uso en el tratamiento de enfermedades y condiciones médicas | |
| MX2023000610A (es) | Inhibidor de trpv4 como agente terapeutico para enfermedades oculares. | |
| KR102591782B9 (ko) | 뇌신경계질환 예방 또는 치료용 약학적 조성물 | |
| BR112022002692A2 (pt) | Agentes antimaláricos | |
| BR112012020377A8 (pt) | utilização de um ou mais selecionado do grupo constituído por um composto da fórmula (i), uma mistura racêmica-diastereomérica e um isômero óptico do referido composto, e um sal farmaceuticamente aceitável e uma pródroga do mesmo, método, composição farmacêutica e kit para tratamento de caquexia e embalagem comercial | |
| BR112022021535A2 (pt) | Métodos para tratar agitação associada ao mal de alzheimer | |
| ES3004543T3 (en) | Dose regimens for use of ly3154207 in the treatment of dopaminergic cns disorders | |
| PH12020550722A1 (en) | Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye | |
| Alonzi et al. | Multiple antimicrobial and immune-modulating activities of cysteamine in infectious diseases | |
| BR112014011336A2 (pt) | composições farmacêuticas que compreendem 7-(1h-imidazol-4-ilmetil)-5,6,7,8-tetra-hidro-quinolina para tratamento de doenças e condições de pele | |
| BR112014001503A2 (pt) | composições farmacêuticas compreendendo 4-bromo-n-(imidazolidin-2-ilideno)-1h-benzimidazol-5-amina para o tratamento de doenças de pele |